AVBP Stock Analysis: Buy, Sell, or Hold?
AVBP - ArriVent BioPharma, Inc. Common Stock
$29.12
-0.06 (-0.21%)
▼
5d:
-1.32%
30d:
-7.67%
90d:
+7.85%
HOLD
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When AVBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AVBP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: AVBP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: AVBP is currently trading at $29.12, which is considered oversold relative to its 30-day fair value range of $29.25 to $31.75.
Technical Outlook: Technically, AVBP is in a uptrend. The price is currently testing key support at $28.57. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AVBP scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (29th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.70 (+53.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AVBP is in a uptrend. The price is currently testing key support at $28.57. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AVBP scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (29th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.70 (+53.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$29.25 -
$31.75
Company Quality Score
58/100
(HOLD)
Options IV Signal
29th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 29th percentile)
- BEARISH: Weak technical setup (37/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 53.5% below Wall St target ($44.70)
Trading Range Analysis
30-Day Trading Range
$29.25 -
$31.75
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$5.17
(17.8%)
Support & Resistance Levels
Support Level
$28.57
Resistance Level
$31.60
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.42
Wall Street Target
$44.70
(+53.5%)
Share & Embed Analysis
Last updated: August 23, 2026 11:24 AM ET
Data refreshes hourly during market hours. Next update: 12:24 PM
Data refreshes hourly during market hours. Next update: 12:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
|
VERA
Vera Therapeutics Inc |
STRONG BUY
14 analysts |
$77 | 57 HOLD |